Background
==========

Twin-to-twin transfusion syndrome (TTTS) complicates 9% of monochorionic twin pregnancies, and if untreated, is associated with a perinatal loss rate of over 80% \[[@B1],[@B2]\]. Fetal interventions, such as repeated serial amnioreduction and laser surgery may reduce the perinatal mortality rate. A recent meta analysis has shown that the overall survival rate varies from 57% to 77% following laser surgery and from 38% to 81% following serial amnioreduction \[[@B3]\].

The first randomized trial comparing amnioreduction with endoscopic laser surgery showed that endoscopic laser surgery resulted in higher survival rates and lower rates of neurologic complications at six months of age than did serial amnioreduction in severe TTTS presenting before 26 weeks of gestation. Therefore, endoscopic laser surgery has been adopted as the first-line treatment for TTTS diagnosed before 26 weeks \[[@B4]\]. As this technique interrupts placental vascular communication, it can potentially reduce neurodevelopmental impairment. Several studies, however, have reported that the incidence of neurodevelopmental impairment in TTTS survivors treated with laser surgery is still high \[[@B5],[@B6]\].

Although amnioreduction is no longer the only treatment option for TTTS, a subset of patients may still benefit from this intervention. Amnioreduction is useful in the setting of TTTS not meeting criteria for laser surgery and in patients in whom laser surgery is not technically possible. Amnioreduction is a relatively simple treatment which does not require sophisticated technical equipment. Previous reports of conservative management have indicated that major neurodevelopmental impairment occurs in 14.3%- 26% of survivors \[[@B7]-[@B10]\].

This study was undertaken to investigate the long-term neurodevelopmental outcome in conservatively treated TTTS.

Methods
=======

We examined the prenatal records of all women and the medical records of children and neonates with TTTS admitted to the Maternity and Perinatal Care Unit of Kyushu University Hospital from January 1996 to December 2004. TTTS was diagnosed in all cases by ultrasound criteria of polyhydramnios (\> 8 cm, deepest vertical pool) in one twin sac and oligohydramnios (‹2 cm, deepest vertical pool) in the co-twin of a monochorionic, diamniotic pregnancy \[[@B11]\]. In our hospital, laser surgery was not performed, so cases with laser surgery were not included.

The following data were obtained from the maternal medical record: gestational age at diagnosis, gestational age at delivery, the stage of TTTS at diagnosis, diagnosis to delivery interval, and amnioreduction. TTTS was staged according to the criteria of Quintero et al. \[[@B12]\]. The following neonatal data were extracted: birth weight and cranial ultrasound findings. Cranial ultrasound scans were obtained in all neonates shortly after birth and further scans were carried out one, three, five, and seven days after birth, followed by weekly scans thereafter until discharge. Additional scanning was undertaken as clinically indicated. Abnormal cranial ultrasound findings in the neonatal period were reviewed for the presence of intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), and ventricular dilatation. Intraventricular hemorrhage (IVH) was classified according to Papile et al. \[[@B13]\]. Periventricular leukomalacia (PVL) was graded according to Vries et al. \[[@B14]\]. Severe cerebral lesions on cranial ultrasound findings were defined as the presence of IVH grade III or IV, and/or PVL ≥ grade II.

All surviving children were offered care in our high-risk infant follow-up program. Repetitive examinations by experienced pediatric neurologists were performed. Their development was evaluated using the Enjoji Developmental Scale \[[@B15]\] before six years of age, followed by the Japanese Wechsler Intelligence Scale for Children-Revised \[[@B16]\] (WISC-R) or Wechsler Preschool Primary Scale of Intelligence at six years or older \[[@B17]\] (WPPSI). Children with normal development had a normal neurological evaluation and developmental quotient (DQ) or intellectual quotient (IQ) \> 85. Minor neurodevelopmental impairment was defined as the presence of at least one of the following: mild cerebral palsy causing motor clumsiness or non-fluent gait, DQ or IQ between 70 and 85. Major neurodevelopmental impairment was defined as the presence of at least one of the following: cerebral palsy, DQ or IQ \< 70, deafness, or blindness. Cerebral palsy was classified as diplegia, hemiplegia, quadriplegia, dyskinetic or mixed \[[@B6],[@B8]\]. Developmental or mental borderline was defined as DQ or IQ between 70 and 85. Developmental or mental retardation was defined as DQ or IQ \< 70 \[[@B15]-[@B17]\].

Statistical analysis
--------------------

Analysis was performed with the SPSS statistical package 16.0 (SPSS Inc, Chicago, IL). Differences between categorical variables were analyzed using the chi-square test or the Fisher exact test as appropriate. Differences between continuous variables were tested using independent sample t-tests. A statistically significant difference was defined as p \< 0.05.

Ethical considerations
----------------------

Ethical permission was obtained, based on the criteria of the Kyushu University research ethics committee concerning observational studies.

Results
=======

Table [1](#T1){ref-type="table"} shows the pregnancy and fetal outcomes with TTTS. During the nine-year study, 21 pregnancies with TTTS were admitted to our center. The gestational age at diagnosis ranged from 18 to 34 weeks with a mean age of 24 weeks. The gestational age at delivery ranged from 22 to 34 weeks with a mean age of 28 weeks. Thirteen pregnancies (61.9%) were treated with serial amnioreduction, with the number of amniocenteses ranging from one to six per pregnancy (mean 2.7). In the eight pregnancies in which amnioreduction was not performed, one pregnancy was complicated by premature rupture of the membrane, two pregnancies presented with mild TTTS (stage I), and one pregnancy opted for delivery. There were two survivors in 42.9% of pregnancies, one survivor in 19% of pregnancies, and no survivors in 38.1% of the pregnancies. The Quintero stage at diagnosis showed 11 pregnancies to be stage I, four pregnancies to be stage II, three pregnancies to be stage III, three pregnancies to be stage IV, and none to be stage V. Intrauterine fetal demise occurred in five fetuses (11.9%), and all of these resulted from pregnancies not treated with amnioreduction. One pregnancy culminated in the intrauterine death of both fetuses, and three pregnancies resulted in the intrauterine death of one fetus. In the three neonates born after the intrauterine fetal demise of their co-twin, one neonate born at 22.4 weeks died soon after birth, one neonate died of heart failure at 75 days of age, and one survivor had mild cerebral palsy with epilepsy and mental retardation. Neonatal death occurred in 13 neonates (35.1%). The overall perinatal mortality rate was 42.9% (18/42). Two infants died after the neonatal period. Twenty-two survivors were followed to at least the age of 1 year corrected for prematurity. Two survivors were lost to follow-up after the age of one year. Neurological follow-up was available for the remaining twenty survivors. The mean age at follow-up was 6.3 years (range, 3-12 years). Fourteen children (70%) had normal neurological development. Six children (30%) had neurodevelopmental impairment.

###### 

Antenatal and delivery characteristics

  ----------------------------------------- ------------
  Pregnancies(n)                            21
  Age (years)                               28 (20-38)
  Parity                                    0 (0-3)
  Gestational age at diagnosis(weeks)       24 (18-34)
  Gestational age at delivery(weeks)        28 (22-34)
  Diagnosis to delivery interval(days)      25 (1-73)
  Use of amnioreduction                     13 (61.9%)
  Amnioreduction per pregnancy              2.7 (1-6)
  Cesarean section                          13 (61.9%)
  Gestational age \< 30 weeks at delivery   15 (71.4%)
  Quintero stage I                          11 (52.4%)
  Quintero stage II                         4 (19%)
  Quintero stage III                        3 (14.3%)
  Quintero stage IV                         3 (14.3%)
  Quintero stage V                          0
  IUFD of 1 twin                            3 (14.3%)
  IUFD of both twins                        1 (4.8%)
  0 survivor\*                              8 (38.1%)
  1 survivor                                4 (19%)
  2 survivors                               9 (42.9%)
                                            
  Fetus(n)                                  42
  Intrauterine fetal death (IUFD)           5 (11.9%)
  Neonatal death                            13 (35.1%)
  Overall perinatal mortality               18 (42.9%)
  Infant death                              2 (5.4%)
  Lost to follow-up                         2 (5.4%)
  Long-term survivors                       20 (54.1%)
  neurodevelopmental impairment             6 (30%)
  ----------------------------------------- ------------

Data shown as mean (range) or n (%) as appropriate.

\*Survivor is defined as the survival of at least 12 months of age.

Of 37 neonates, four died before the cranial ultrasound scan was performed. Abnormal ultrasound findings were present in seventeen (51.5%) of 33 neonates as follows: IVH grade I in five neonates; IVH grade І in three neonates; IVH grade I + III in two neonates; PVL grade I in three neonates; PVL grade І in two neonates; and mild ventricular dilatation in two neonates. Of seventeen neonates with abnormal cranial ultrasound findings, neonatal death occurred in five neonates; infant death occurred in two infants; one survivor was lost to follow-up; five of the nine survivors had neurodevelopmental impairment. A severe cerebral lesion was present in four neonates (12.1%). One neonate born at 24 weeks died of heart failure at one day of age. One neonate whose co-twin died at 26 weeks of gestation died of heart failure at 75 days of age. Two survivors had major neurodevelopmental impairment. On 16 neonates with normal cranial ultrasound findings, neonatal death occurred in four neonates; one survivor was lost to follow-up; and one survivor had minor neurodevelopmental impairment.

Table [2](#T2){ref-type="table"} shows adverse neurodevelopmental outcomes with TTTS. Four children (20%) had major neurodevelopmental impairment. For case 1 (in which fetal death of the donor co-twin occurred at 25 weeks of gestation), birth occurred at 27 weeks of gestation. The child was found to have mental retardation (IQ 61) and epilepsy with mild cerebral palsy causing a non-fluent gait. Case 2 (PVL (grade І)) had mental retardation (IQ 69). Case 3 had mild bilateral ventricular dilatation and mental retardation (IQ 54). Case 4 had posthemorrhagic hydrocephalus and mild cerebral palsy causing motor clumsiness. Because the child\'s IQ was exactly 70, the case was classified as borderline mental impairment. However, we considered case 4 to have major neurodevelopmental impairment in this study on the basis of general clinical judgment.

###### 

Data of the 6 surviving twins with adverse neurodevelopmental outcomes

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   D/R   Quintero\   GA\             GA\         AR\   Birth\    Neonatal cranial\        Follow-up\   Neurodevelopmental\   IQ             Outcome of co-twin    Severity
               stage       at diagnosis\   at birth\   (n)   weight\   ultrasound findings      age\         Impairment                                                 
                           (weeks)         (weeks)           (g)                                (years)                                                                 
  ------ ----- ----------- --------------- ----------- ----- --------- ------------------------ ------------ --------------------- -------------- --------------------- ----------
  1      R     III         19              27          0     814       IVH I                    6            Mild CP, epilepsy,\   61(6 years)    IUFD                  major
                                                                                                             Mental retardation                                         

  2      R     I           20              28          4     1018      PVL І                    8            Mental retardation    69(6 years)    mental borderline     major

  3      R     II          26              27          1     1130      mild bilateral\          7            Mental retardation    54(6 years)    Infant death          \
                                                                       ventricular dilatation                                                                           major

  4      D     I           21              28          0     865       IVH III                  12           Mild CP,\             70(12 years)   Mild CP,\             major
                                                                                                             mental borderline\                   mental borderline     
                                                                                                             hydrocephalus                                              

  5      R     I           21              28          0     975       IVH I                    12           Mild CP,\             78(12 years)   Mild CP,\             minor
                                                                                                             Mental borderline                    mental borderline,\   
                                                                                                                                                  hydrocephalus         

  6      D     I           20              28          4     886       normal                   8            Mental borderline     71(6 years)    mental retardation    minor
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

R = Recipient, D = Donor, GA = Gestational age, AR = Amnioreductions

IVH = Intraventricular hemorrhage, PVL = periventricular leukomalacia; CP = cerebral palsy,

IUFD = intrauterine fetal death, IQ = intellectual quotient.

Two children (10%) had minor neurodevelopmental impairment. Case 5 had borderline mental impairment (IQ 78) and mild cerebral palsy causing motor clumsiness while case 6 had borderline mental impairment only (IQ 71). Case 2/case 6 and case 4/case 5 comprised the pairs in two twin pregnancies. All of them were delivered before 29 weeks of gestation.

Table [3](#T3){ref-type="table"} shows antenatal and delivery characteristics in surviving cases without neurodevelopmental complications as well as those complicated by death or neurodevelopmental impairment. The mean gestational age for those surviving without complication at diagnosis and delivery was 28 weeks (range, 24 - 34 weeks) and 31 weeks (range, 27-34 weeks), respectively and the mean gestational age for those with death or neurodevelopmental impairment at diagnosis and delivery was 22 weeks (range, 19 - 27 weeks) and 27 weeks (range, 22 - 31 weeks), respectively. Overall, the mean gestational age for those with death or neurodevelopmental impairment was lower than surviving cases without neurodevelopmental impairment. The interval between diagnosis and delivery was significantly longer and the birth weight was significantly lower in those complicated by death or neurodevelopmental impairment. There was no difference in the ratio of Donors to Recipients between the groups.

###### 

Comparison of normal development and death or neurodevelopmental impairment

  ----------------------------------------------------------------------------------------------------------
                                    Normal development   Death or Neurodevelopmental impairment   *P*value
  --------------------------------- -------------------- ---------------------------------------- ----------
  Number                            14                   26                                       

  Gestational age at diagnosis\     28 (24-34)           22 (19-27)                               \< 0.001
  (weeks)                                                                                         

  Gestational age at delivery\      31 (27-34)           27 (22-31)                               \< 0.001
  (weeks)                                                                                         

  Diagnosis to delivery interval\   15 (2-34)            32 (1-50)                                0.002
  (days)                                                                                          

  Birth weight\                     1355 (750-2130)      812 (255-1970)                           0.001
  (g)                                                                                             

  Donor/Recipient                   7/7                  13/13                                    0.999
  ----------------------------------------------------------------------------------------------------------

Data shown as mean (range) or n as appropriate.

Table [4](#T4){ref-type="table"} shows perinatal outcomes and survivors\' outcomes between amnioreduction and non-amnioreduction. There was no significant difference in the mean gestational age at delivery, diagnosis to delivery interval, or neurodevelopmental impairment.

###### 

Perinatal outcomes and survivor\' outcomes between amnioreduction (AR) and non-amnioreduction (non-AR)

  ------------------------------------------------------------------------------------
                                         AR                non-AR           *P*value
  -------------------------------------- ----------------- ---------------- ----------
  Number                                 26                16               *NS*

  Gestational age at diagnosis (weeks)   25 (18-32)        23 (19-34)       *NS*

  Gestational age at delivery (weeks)    28 (24-34)        27 (22-34)       *NS*

  Diagnosis to delivery interval\        22 (4-56)         30 (1-73)        *NS*
  (days)                                                                    

  Birth weight (g)                       1124 (335-2222)   921 (255-2138)   *NS*

  IUFD                                   0                 5 (31.2%)        *NS*

  Neonatal death                         10 (38.5%)        3 (27.3%)        *NS*

  Infant death                           1 (3.8%)          1 (9.1%)         *NS*

  Lost to follow-up                      2 (7.7%)          0                *NS*

  Long-term survivors                    13 (50%)          7 (63.6%)        *NS*

  Neurodevelopmental impairment          3 (23.1%)         3 (42.9%)        *NS*
  ------------------------------------------------------------------------------------

Data shown as mean (range) or n (%) as appropriate.

NS, not significant; IUFD, intrauterine fetal death.

Discussion
==========

In this study, we reported that the overall perinatal mortality rate in conservatively treated patients with TTTS was 42.9%. The result was similar to the mortality reported by Mari *et al*. \[[@B18]\], Gray *et al*. \[[@B19]\], and Senat *et al*. \[[@B4]\].

We found that 30% of surviving twins had neurodevelopmental impairment when TTTS was treated conservatively. Four children (20%) had major neurodevelopmental impairment. Two children (10%) had minor neurodevelopmental impairment. Cincotta et al. observed 17 pregnancies, of which 12 (71%) were treated with serial amnioreduction \[[@B9]\]. Twenty-three children were followed up at least two years. Five survivors (22%) had major neurological morbidity, which was similar to our results. Dickinson et al. \[[@B7]\] investigated 52 surviving infants from 31 pregnancies, with 22 pregnancies treated with serial amnioreduction. 49 children were followed up at a median age of five years. Major neurodevelopmental disability was present in seven children (14.3%). Minor neurodevelopmental impairment was not reported. Mari et al. investigated 42 survivors of TTTS after aggressive amnioreduction \[[@B20]\]. Cerebral palsy was diagnosed in two of 42 infants (4.7%). No developmental tests were used and the incidence of major neurodevelopmental impairment was lower. With regard to overall neurodevelopmental impairment, we found the incidence was lower than several studies previously reported in analyses of long-term neurological outcome \[[@B8],[@B10],[@B21]\]. Lopriore et al. investigated 29 pregnancies, including 18 pregnancies (62%) with serial amnioreduction \[[@B10]\]. Twenty-nine children were followed up to a mean age of 6.2 years (4-11). Major neurodevelopmental impairment was observed in 21% of children, and minor neurodevelopmental impairment (mild speech delay) was seen in 17.2% (5/29). Haverkamp et al. described 40 children who were followed up to a mean age of 24 months \[[@B21]\]. Major neurodevelopmental impairment was seen in 23%, while minor neurodevelopmental impairment was found in 33%. Frusca et al. investigated 31 children who were followed up to a mean age of 24 months \[[@B8]\]. Eight children (25.8%) had major neurologic disabilities; five children (16.1%) had minor neurologic disabilities. This discrepancy may be due to the heterogeneity within the neurodevelopmental impairment of TTTS and assessment of neurodevelopmental outcome.

Abnormal cranial ultrasound findings were found in seventeen cases (51.5%) of the 33 neonates who underwent cranial ultrasound scans. Denbow *et al*. reported an even higher incidence (58%) of neonates with abnormal cranial ultrasound findings \[[@B2]\]. Gestational age at delivery and birth weight were not associated with an incidence of abnormal cranial ultrasound findings. Cranial ultrasound scans at birth are commonly used as a surrogate marker for neurodevelopmental outcome in later life \[[@B22]\]. Periventricular white matter lesions (WMLs) and persistent ventriculomegaly in particular have been associated with an adverse neurodevelopmental outcome \[[@B22],[@B23]\]. In our patient group, five cases (15.2%) showed WMLs. Some studies have shown evidence of cerebral white matter lesions in one third of monochorionic twin infants at birth, particularly when the pregnancy was complicated by long-term coexistence with a co-twin intrauterine demise \[[@B24],[@B25]\]. Hecher *et al*. \[[@B26]\] reported a lower incidence (6%) of cerebral WMLs following laser surgery, compared with the cases treated by amnioreduction (18%). Results from observational studies \[[@B2],[@B10],[@B27]\] and an international multicenter registry \[[@B18],[@B28]\] of TTTS treated by amnioreduction suggest that the incidence of major cranial abnormalities ranges between 18 and 41%. Discrepancies among results may be due to differences in diagnostic criteria, disease onset, severity of the TTTS, treatment modalities, and stratification of cranial lesions.

Since laser surgery for TTTS was introduced, survival rates have been increasing. Neurodevelopmental impairment, however, is still relatively common. Sutcliffe et al. investigated 67 children with severe TTTS treated by laser surgery, and 9% had cerebral palsy \[[@B29]\]. They did not report the number of infants with developmental delay. Banek et al. investigated 89 children after TTTS treated by laser surgery between 14 months and 44 months. Eleven percent of the children had minor neurologic deficiencies, and an equal portion had major neurologic deficiencies \[[@B5]\]. Graef et al. investigated 167 children from TTTS treated by laser surgery and followed to a median age of 38 months (14 - 53) \[[@B30]\]. In this group, 7.2% of the children showed minor neurologic abnormalities, and 6% showed major neurologic abnormalities. Both studies originated from the same research group in Germany. The largest analysis concerning long-term neurodevelopmental outcome after TTTS with laser surgery was published by Lopriore et al. \[[@B6]\]. They investigated 278 children at two years of age (corrected for prematurity). The incidence of major neurodevelopmental impairment was 18%. They did not report minor neurodevelopmental impairment.

Whether TTTS is treated with laser surgery or managed conservatively, the incidence of major neurodevelopmental impairment is high. The pathogenesis of cerebral injury in TTTS is not clearly defined. Cerebral injury in TTTS may result from antenatal injury secondary to hemodynamic and hematological imbalance \[[@B21]\] and/or from postnatal injury associated with prematurity \[[@B31]\] and low birth weight \[[@B8]\]. In our study, the long-term outcomes for the survivors with TTTS were relatively good when survivors were delivered after 29 weeks of gestation. Mari et al. found that long-term outcomes for the twins with TTTS were excellent when both fetuses were delivered alive after 27 weeks of gestation \[[@B20]\]. A research group from Germany reported that neurodevelopmental disability in infants who were born before 32 weeks of gestation was significantly higher \[[@B5],[@B30]\]. Lopriore et al. and Lenclen et al. showed that early gestational age at delivery was a risk factor for neurodevelopmental impairment \[[@B6],[@B32]\]. It seems that prolongation of gestation is central in management strategies.

The results of the present study suggest that the outcomes, particularly neurodevelopmental, resulting from the conservative management of TTTS are not markedly different from outcomes obtained with laser surgery. The strength of our conclusion is limited by the small study size and the preponderance of mild cases which presented later\[[@B6]\]. While immediate neonatal survival may be improved with laser surgery, this advantage may be lost with long term follow-up.

Conclusions
===========

In conclusion, the primary predictor for neurodevelopmental impairment is gestational age, regardless of whether the management is conservative or by laser surgery. Therefore, prolongation of gestation is important. Additionally, we suggest performing a routine cranial ultrasound examination after birth as the results will be valuable in predicting long-term neurodevelopmental outcomes.
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